Companies / Prime Medicine, Inc.

Prime Medicine, Inc.

Nasdaq: PRMECIK 1894562CAMBRIDGE, MA

Financials · FY2025

Revenue$4.63M
Net income$-201.14M
Total debt—
Cash$47.45M
Diluted EPS$-1.35
Shares outstanding181.4M

Ownership

181.4M shares outstanding · as of Jul 31, 2026
3.3%10%+ / strategic
Ownership
10%+ / strategic3.31%5,995,183
Institutions52.95%96,045,358
Public float43.74%79,336,315

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 5

View all →
Insider% of sharesShares
Alenson CarmanFormerSee Remarks
——
Foster-Cheek Kaye IDirector
——
Lee Ann L.Chief Technical Officer
——
Nelsen RobertDirector · 10% owner
——
Reine AllanCEOChief Executive Officer · Director
——

Institutional holders 189

View all →
HolderValue% of shares
Alphabet Inc.$61.12M9.13%
BlackRock, Inc.$35.43M5.29%
State Street Corporation$27.96M4.18%
Vanguard Group Inc$22.44M3.57%
ARK Investment Management LLC$18.63M2.96%
Balyasny Asset Management L.P.$14.35M2.27%
Sumitomo Mitsui Trust Group, Inc.$11.26M1.79%
Amova Asset Management Americas, Inc.$11.20M1.79%
Casdin Capital, LLC$10.99M1.75%
Woodline Partners LP$10.42M1.66%

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q3 2025
as of
Farallon Capital Management LLC
13F manager
NewCommon Stock$26.32M+4.8M
4,750,000
2.62% of shares
medium
Q4 2025
as of
Farallon Capital Management LLC
13F manager
TrimCommon Stock$-12.18M-3.5M
-73.88%
1,240,843
0.68% of shares
medium
Q2 2026
as of
State Street Corporation
13F manager
AddCommon Stock$9.15M+2.5M
+48.69%
7,576,460
4.18% of shares
medium
Q2 2026
as of
BlackRock, Inc.
13F manager
AddCommon Stock$4.92M+1.3M
+16.12%
9,602,041
5.29% of shares
low
Q1 2026
as of
Balyasny Asset Management L.P.
13F manager
AddCommon Stock$3.48M+999K
+31.97%
4,123,365
2.27% of shares
low
Q4 2025
as of
Bank of America Corp /De
13F manager
AddCommon Stock$1.86M+537K
+484.63%
648,012
0.36% of shares
low
Q1 2026
as of
Renaissance Technologies LLC
13F manager
TrimCommon Stock$-1.42M-408K
-35.51%
741,039
0.41% of shares
low
Q4 2025
as of
Barclays PLC
13F manager
AddCommon Stock$860.3K+248K
+213.91%
363,826
0.20% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
T. Rowe Price Investment Management, Inc.Passive13G/A—5,995,183—

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
PRMECommon StockEquity74168J101BBG011RT3R55